CCL2 and vascular disorder: A small, synthetic indazolic derivative that preferentially inhibits transcription of the monocyte chemoattractant subfamily of CC chemokines (MCP-1/CCL2, MCP-2/CCL8 and MCP-3/CCL7) [33], bindarit has shown clinical efficacy in a broad array of experimental inflammatory, autoimmune and vascular disorders involving peripheral organ beds [34-38], as well as success in recent clinical trials for diabetic nephropathy [39] and lupus nephritis [40].